OncoHost is a precision diagnostics company centered on predictive biomarker development for improved patient care. Its PROphet® NSCLC Test provides physicians crucial guidance on optimal first-line immunotherapy treatment plans, significantly affecting overall survival. Led by an experienced team of entrepreneurs & industry experts & supported by a large-scale prospective clinical trial with over 40 sites & 1700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics & biomarker development to the next stage.